The Shifting Cancer Landscape:
Trends, Care Navigation, and Early-Onset Cancer

Speaker Biographies
(In order of appearance on the program)

October 27, 2026
2 pm – 3 pm ET

Caitlin (Cait) Ellis, MPA, serves as NIHCM's Vice President, providing strategic leadership across the organization to support NIHCM's work to improve health care through policy research, education, and innovation.

In her role, Ms. Ellis oversees the Foundation's programming portfolio — policy research and journalism grants, awards, and policy communications — with a focus on enhancing the affordability and quality of health care in the United States. Her areas of interest include the drivers and impacts of rising health care costs, market dynamics, maternal and child health, behavioral health, and social determinants of health.

Ms. Ellis joined NIHCM in 2014 and has held several key leadership roles. She holds a Master of Public Affairs from the Paul H. O'Neill School of Public and Environmental Affairs at Indiana University Bloomington, and a Bachelor of Arts in Politics from Willamette University.

Janet S. de Moor, PhD, MPH, is the Associate Director of the National Cancer Institute's (NCI's) Division of Cancer Control and Population Science's (DCCPS) Healthcare Delivery Research Program (HDRP). In this role, Dr. de Moor leads a team at NCI whose mission is to serve as a catalyst for the field of healthcare delivery research and to enhance data resources, measures, and NCI's grant portfolio in this area. An experienced scientist with training in public health and behavioral science, Dr. de Moor has developed and managed cancer control and population science research programs as an extramural investigator, an NCI program director, and, most recently, as deputy and acting associate director of HDRP. Dr. de Moor's work has centered around three major areas: how individuals manage the physical, psychological, and economic demands of a cancer diagnosis; how broader social and economic forces shape access to guideline-recommended care; and how providers and healthcare systems adapt to innovations in care delivery.

Dr. de Moor received her Master of Public Health degree (2000) and Doctorate in Behavioral Science (2004) from the University of Texas Health Science Center at Houston School of Public Health and completed a postdoctoral fellowship at Harvard School of Public Health and Dana-Farber Cancer Institute (2006). Before coming to NCI in 2011, Dr. de Moor was an Assistant

Professor in the Division of Health Behavior and Health Promotion at The Ohio State University College of Public Health.

Thomas Graf, MD, is the Chief Medical Officer for Florida Blue Medicare. He is responsible for Quality, Pharmacy, Care, and Utilization Management for Florida Blue Medicare members, and for supporting the provider network.

Prior to Florida Blue Medicare, Dr. Graf spent 25 years as a family physician, including as a Residency Director and Senior Associate Dean for Clinical Affairs, as a consultant with Chartis, and as a clinical leader in IDNs, including Ascension national and Geisinger.

Dr. Graf is a board-certified Family Physician. He received his medical degree from the University of Michigan and completed his residency at Henry Ford Health System.

Veda Giri, **MD**, is Professor of Medicine at Yale University and is a medical oncologist with specialization in clinical cancer genetics. She serves as Division Chief of Clinical Cancer Genetics for Yale School of Medicine, Director of the Cancer Genetics and Prevention Program, and Director of the Early-Onset Cancer Program at Yale Cancer Center.

As Director of Cancer Genetics and Prevention, Dr. Giri leads a comprehensive effort in genetic evaluation for precision medicine, tailored cancer screening, and hereditary cancer assessment across patient populations. She is the Principal Investigator of multiple grant-funded cancer genetic evaluation studies spanning genetic counseling, genetic testing, disparities, behavioral science, and implementation research with a focus on prostate cancer.

As Director of the Early-Onset Cancer Program, Dr. Giri is leading a cutting-edge translational effort to address clinical, research, and psychosocial needs of patients with early-onset cancers. Dr. Giri serves on several national committees, including the National Comprehensive Cancer Network, NIH PDQ® Cancer Genetics Editorial Board, American Society of Clinical Oncology, and American Urologic Association, contributing expertise in cancer genetics at the national level.